New Acquisition Expands Sequencing Install Base to 37 Illumina Genome Analyzers
News Nov 14, 2008
Illumina, Inc. has announced that the Wellcome Trust Sanger Institute has purchased 11 additional Genome Analyzers, increasing the organization's total number of the Illumina sequencing platform to 37.
The continued scale up on the Genome Analyzer will support the Sanger Institute's many initiatives, such as its contribution to the 1000 Genome Project.
"The Sanger Institute has an important international role in producing and analyzing genomic data. That role is founded in DNA sequencing and we will meet new challenges by investing in appropriate new technologies," said Professor Julian Parkhill, Ph.D., Director of Sequencing at the Wellcome Trust Sanger Institute.
"We are expanding our ability to contribute to major projects on human and mouse genome resequencing, pathogen genomics and genetics, and cancer genetics and to carry out our own research programmes within the Institute strategy," said Parkhill.
Generating over 20GB of data on internal systems, the Genome Analyzer offers the highest rate of daily output and the user friendly workflow. The Genome Analyzer also offers a set of supported applications, including those used to profile and discover novel miRNA, to create a high-resolution genome-wide map of DNA-protein binding sites.
Research Team Discovers Compound that Stops Cancer From SpreadingNews
Using a mouse model, OHSU physician-scientists lead effort to hone a drug that inhibits cancer cells from spreading to other areas in the body.READ MORE
Mechanism Controlling Multiple Sclerosis Risk IdentifiedNews
Researchers at Karolinska Institutet have now discovered a new mechanism of a major risk gene for multiple sclerosis (MS) that triggers disease through so-called epigenetic regulation. They also found a protective genetic variant that reduces the risk for MS through the same mechanism.
Synthetic DNA Shuffling Enzyme Outpaces Natural CounterpartNews
A new synthetic enzyme, crafted from DNA rather than protein, flips lipid molecules within the cell membrane, triggering a signal pathway that could be harnessed to induce cell death in cancer cells. Researchers say their lipid-scrambling DNA enzyme is the first in its class to outperform naturally occurring enzymes – and does so by three orders of magnitudeREAD MORE